Company Focus
Novartis
Latest Novartis News
Pharmaceutical
Novartis has reported new data showing that its investigational BTK inhibitor, remibrutinib, significantly improves sleep quality for patients with chronic spontaneous urticaria (CSU). The findings, from the Phase III REMIX-1 and REMIX-2 trials, were presented at the American Academy of Dermatology annual meeting in Orlando. 10 March 2025
Related News
Insights
Company Spotlight
A private, clinical-stage biopharmaceutical company committed to developing best-in-class, novel therapy for the treatment of hypertension.
Latest News & Features of interest to Novartis
Pharmaceutical
Guaranteed success in drug development does not exist, such are the inherent risks, potential pitfalls and costs involved. 14 March 2025
Biotechnology
Sutro Biopharma, a US biotechnology company, has announced significant organizational changes, including a workforce reduction of nearly 50%, a shift in its drug development focus, and leadership transitions. 14 March 2025
Pharmaceutical
Swiss drugmaker Idorsia has announced the publication of a Phase IV study in the Journal of Sleep Research. 14 March 2025
Biotechnology
US pre-clinical biotech start-up Montara Therapeutics, which is pioneering brain-selective therapies for CNS diseases, has announced the closing of a $20 million oversubscribed expansion of its Series Seed financing. 14 March 2025
Biotechnology
MeiraGTx has entered into a strategic partnership with artificial intelligence firm Hologen to accelerate the Phase III development of AAV-GAD, a gene therapy for Parkinson’s disease. 13 March 2025
Biotechnology
Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today announced a research and license agreement with German family-owned pharma major Boehringer Ingelheim to accelerate the development of multiple drug targets. 13 March 2025
Biotechnology
Prague headquartered clinical-stage SOTIO Biotech, which is owned by the Czech Republic's PPF Group, today announced it will be exercising its option, under its license and option agreement with Synaffix, a Lonza company, to obtain a license to Synaffix’s technology to develop two bispecific antibody-drug conjugate (ADC) programs. 13 March 2025
Pharmaceutical
UK-based Sareum Holdings (AIM: SAR), a biotech developing kinase inhibitors for autoimmune disease and cancer, has acquired the licence for SRA737 following the program’s return from an undisclosed USA-based biopharma. 13 March 2025
Pharmaceutical
The European Commission (EC) has approved Danish CNS specialist Lundbeck and Otsuka Pharmaceutical Europe’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older. 13 March 2025
Pharmaceutical
California-based Vivace Therapeutics has announced the closing of a $35 million Series D financing. 13 March 2025
Latest In Brief for Novartis
Pharmaceutical
Israel-based radiopharma company Isotopia has launched Isoprotrace in Germany, supported by distribution partner DSD Pharma. 10 March 2025
Latest Ones To Watch News
Shares of US biotech 2seventy Bio skyrocketed almost 76% to $4.92 today, as it agreed to a takeover bid from US pharma major Bristol Myers Squibb, which is looking to enhance its CAR T-cell therapy business. 11 March 2025
10 March 2025
26 February 2025
Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze